Compare Dollar General Corp. (DG) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar General Corp. vs Sana Biotechnology Inc — how do they compare? Dollar General Corp. trades at $127.23 (market cap $27.42B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Dollar General Corp. is far larger — about 32.8× Sana Biotechnology Inc's market cap, and Dollar General Corp. pays a 1.9% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dollar General Corp. for 59 Days and Sana Biotechnology Inc for 23 Days on average.
| DG | SANA | |
|---|---|---|
Market Cap | $27.42B | $836.71M |
Volume | 2,291,517 | 4,507,444 |
Sector | Consumer Staples | Health |
52-Week High | $156.26 | $5.92 |
52-Week Low | $95.94 | $2.68 |
Typical Hold Time | 59 Days | 23 Days |
Enterprise Value | $41.60B | $749.96M |
Dividend Yield | 1.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar General (DG) trades at $127.23, up 4.15% today, showing strong momentum with three consecutive quarterly earnings beats. The stock exhibits bullish technical signals with moving averages supporting upward movement. Fundamentally, DG maintains solid profitability with 19.69% ROE and attractive valuation metrics including P/E of 16.14 and P/S of 0.63. Recent developments include tariff refunds boosting margins and expansion of same-day delivery through Instacart partnerships.
The outlook remains positive with analyst consensus targeting $137.27, representing 7.9% upside potential. Key opportunities include margin expansion from tariff benefits and retail media network growth, while risks involve consumer spending pressure and competitive discount retail landscape. With 56% analyst buy ratings and improving cash flow trends, DG presents a compelling value proposition in the retail sector.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with no revenue, negative EBITDA of -$192.96M, and deeply negative ROE of -152.87%. Technical indicators show bearish momentum with moving averages signaling sell pressure, though oscillators remain neutral. The company continues to burn cash with -$55.33M net cash flow in 2025, relying on financing activities to fund operations while advancing its cell therapy pipeline through multiple investor presentations.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA represents a high-risk biotech investment with substantial execution risk. The absence of revenue, persistent losses, and cash burn require careful monitoring of clinical milestones. Near-term catalysts depend on pipeline progress, but shareholders face dilution risk from continued financing needs amid challenging technical conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
